nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—ABCB1—lung cancer	0.353	1	CbGaD
Nadolol—ABCB1—Topotecan—lung cancer	0.0566	0.136	CbGbCtD
Nadolol—ABCB1—Gefitinib—lung cancer	0.0518	0.124	CbGbCtD
Nadolol—ABCB1—Vinorelbine—lung cancer	0.0399	0.0958	CbGbCtD
Nadolol—ABCB1—Crizotinib—lung cancer	0.0317	0.0762	CbGbCtD
Nadolol—ABCB1—Gemcitabine—lung cancer	0.031	0.0745	CbGbCtD
Nadolol—ABCB1—Erlotinib—lung cancer	0.0306	0.0735	CbGbCtD
Nadolol—ABCB1—Paclitaxel—lung cancer	0.028	0.0673	CbGbCtD
Nadolol—ABCB1—Irinotecan—lung cancer	0.0277	0.0664	CbGbCtD
Nadolol—ABCB1—Vinblastine—lung cancer	0.0246	0.059	CbGbCtD
Nadolol—ABCB1—Cisplatin—lung cancer	0.0225	0.0541	CbGbCtD
Nadolol—ABCB1—Etoposide—lung cancer	0.0221	0.0532	CbGbCtD
Nadolol—ABCB1—Docetaxel—lung cancer	0.0203	0.0486	CbGbCtD
Nadolol—ABCB1—Doxorubicin—lung cancer	0.0151	0.0363	CbGbCtD
Nadolol—ABCB1—Methotrexate—lung cancer	0.0146	0.0351	CbGbCtD
Nadolol—Lethargy—Methotrexate—lung cancer	0.000269	0.00136	CcSEcCtD
Nadolol—Hypertension—Gemcitabine—lung cancer	0.000268	0.00135	CcSEcCtD
Nadolol—Asthenia—Topotecan—lung cancer	0.000265	0.00133	CcSEcCtD
Nadolol—Chest pain—Gemcitabine—lung cancer	0.000265	0.00133	CcSEcCtD
Nadolol—Alopecia—Paclitaxel—lung cancer	0.000264	0.00133	CcSEcCtD
Nadolol—Agranulocytosis—Docetaxel—lung cancer	0.000263	0.00133	CcSEcCtD
Nadolol—Asthenia—Erlotinib—lung cancer	0.000262	0.00132	CcSEcCtD
Nadolol—Pruritus—Topotecan—lung cancer	0.000261	0.00131	CcSEcCtD
Nadolol—Oedema—Irinotecan—lung cancer	0.00026	0.00131	CcSEcCtD
Nadolol—Diarrhoea—Vinblastine—lung cancer	0.00026	0.00131	CcSEcCtD
Nadolol—Pruritus—Erlotinib—lung cancer	0.000258	0.0013	CcSEcCtD
Nadolol—Flatulence—Paclitaxel—lung cancer	0.000256	0.00129	CcSEcCtD
Nadolol—Shock—Irinotecan—lung cancer	0.000256	0.00129	CcSEcCtD
Nadolol—Oedema—Gemcitabine—lung cancer	0.000254	0.00128	CcSEcCtD
Nadolol—Diarrhoea—Topotecan—lung cancer	0.000252	0.00127	CcSEcCtD
Nadolol—Cardiac failure congestive—Doxorubicin—lung cancer	0.000252	0.00127	CcSEcCtD
Nadolol—Irritability—Methotrexate—lung cancer	0.000252	0.00127	CcSEcCtD
Nadolol—Hyperhidrosis—Irinotecan—lung cancer	0.000252	0.00127	CcSEcCtD
Nadolol—Dizziness—Vinblastine—lung cancer	0.000251	0.00126	CcSEcCtD
Nadolol—Mood swings—Methotrexate—lung cancer	0.00025	0.00126	CcSEcCtD
Nadolol—Diarrhoea—Erlotinib—lung cancer	0.00025	0.00126	CcSEcCtD
Nadolol—Body temperature increased—Vinorelbine—lung cancer	0.00025	0.00126	CcSEcCtD
Nadolol—Anorexia—Irinotecan—lung cancer	0.000248	0.00125	CcSEcCtD
Nadolol—Vision blurred—Paclitaxel—lung cancer	0.000245	0.00123	CcSEcCtD
Nadolol—Hyperhidrosis—Gemcitabine—lung cancer	0.000245	0.00123	CcSEcCtD
Nadolol—Visual impairment—Docetaxel—lung cancer	0.000244	0.00123	CcSEcCtD
Nadolol—Dizziness—Topotecan—lung cancer	0.000244	0.00123	CcSEcCtD
Nadolol—Hypotension—Irinotecan—lung cancer	0.000243	0.00122	CcSEcCtD
Nadolol—Anorexia—Gemcitabine—lung cancer	0.000242	0.00122	CcSEcCtD
Nadolol—Vomiting—Vinblastine—lung cancer	0.000242	0.00122	CcSEcCtD
Nadolol—Dizziness—Erlotinib—lung cancer	0.000241	0.00122	CcSEcCtD
Nadolol—Hypotension—Gemcitabine—lung cancer	0.000237	0.00119	CcSEcCtD
Nadolol—Oedema—Cisplatin—lung cancer	0.000236	0.00119	CcSEcCtD
Nadolol—Insomnia—Irinotecan—lung cancer	0.000235	0.00119	CcSEcCtD
Nadolol—Vomiting—Topotecan—lung cancer	0.000235	0.00118	CcSEcCtD
Nadolol—Cardiac failure—Doxorubicin—lung cancer	0.000234	0.00118	CcSEcCtD
Nadolol—Paraesthesia—Irinotecan—lung cancer	0.000234	0.00118	CcSEcCtD
Nadolol—Syncope—Paclitaxel—lung cancer	0.000233	0.00117	CcSEcCtD
Nadolol—Loss of consciousness—Etoposide—lung cancer	0.000233	0.00117	CcSEcCtD
Nadolol—Lethargy—Doxorubicin—lung cancer	0.000233	0.00117	CcSEcCtD
Nadolol—Rash—Topotecan—lung cancer	0.000233	0.00117	CcSEcCtD
Nadolol—Dermatitis—Topotecan—lung cancer	0.000232	0.00117	CcSEcCtD
Nadolol—Vomiting—Erlotinib—lung cancer	0.000232	0.00117	CcSEcCtD
Nadolol—Dyspnoea—Irinotecan—lung cancer	0.000232	0.00117	CcSEcCtD
Nadolol—Cough—Etoposide—lung cancer	0.000232	0.00117	CcSEcCtD
Nadolol—Rash—Erlotinib—lung cancer	0.00023	0.00116	CcSEcCtD
Nadolol—Dermatitis—Erlotinib—lung cancer	0.00023	0.00116	CcSEcCtD
Nadolol—Insomnia—Gemcitabine—lung cancer	0.000229	0.00115	CcSEcCtD
Nadolol—Dyspepsia—Irinotecan—lung cancer	0.000229	0.00115	CcSEcCtD
Nadolol—Hypertension—Etoposide—lung cancer	0.000229	0.00115	CcSEcCtD
Nadolol—Loss of consciousness—Paclitaxel—lung cancer	0.000229	0.00115	CcSEcCtD
Nadolol—Diplopia—Doxorubicin—lung cancer	0.000229	0.00115	CcSEcCtD
Nadolol—Hyperhidrosis—Cisplatin—lung cancer	0.000228	0.00115	CcSEcCtD
Nadolol—Paraesthesia—Gemcitabine—lung cancer	0.000228	0.00115	CcSEcCtD
Nadolol—Cough—Paclitaxel—lung cancer	0.000227	0.00114	CcSEcCtD
Nadolol—Asthenia—Vinorelbine—lung cancer	0.000226	0.00114	CcSEcCtD
Nadolol—Decreased appetite—Irinotecan—lung cancer	0.000226	0.00114	CcSEcCtD
Nadolol—Dyspnoea—Gemcitabine—lung cancer	0.000226	0.00114	CcSEcCtD
Nadolol—Chest pain—Etoposide—lung cancer	0.000226	0.00114	CcSEcCtD
Nadolol—Nausea—Vinblastine—lung cancer	0.000226	0.00114	CcSEcCtD
Nadolol—Anorexia—Cisplatin—lung cancer	0.000225	0.00113	CcSEcCtD
Nadolol—Affect lability—Doxorubicin—lung cancer	0.000225	0.00113	CcSEcCtD
Nadolol—Hypertension—Paclitaxel—lung cancer	0.000225	0.00113	CcSEcCtD
Nadolol—Fatigue—Irinotecan—lung cancer	0.000224	0.00113	CcSEcCtD
Nadolol—Alopecia—Docetaxel—lung cancer	0.000224	0.00113	CcSEcCtD
Nadolol—Pruritus—Vinorelbine—lung cancer	0.000223	0.00112	CcSEcCtD
Nadolol—Pain—Irinotecan—lung cancer	0.000223	0.00112	CcSEcCtD
Nadolol—Constipation—Irinotecan—lung cancer	0.000223	0.00112	CcSEcCtD
Nadolol—Chest pain—Paclitaxel—lung cancer	0.000221	0.00111	CcSEcCtD
Nadolol—Hypotension—Cisplatin—lung cancer	0.000221	0.00111	CcSEcCtD
Nadolol—Decreased appetite—Gemcitabine—lung cancer	0.00022	0.00111	CcSEcCtD
Nadolol—Nausea—Topotecan—lung cancer	0.000219	0.0011	CcSEcCtD
Nadolol—Abdominal discomfort—Methotrexate—lung cancer	0.000219	0.0011	CcSEcCtD
Nadolol—Fatigue—Gemcitabine—lung cancer	0.000219	0.0011	CcSEcCtD
Nadolol—Pain—Gemcitabine—lung cancer	0.000217	0.00109	CcSEcCtD
Nadolol—Constipation—Gemcitabine—lung cancer	0.000217	0.00109	CcSEcCtD
Nadolol—Nausea—Erlotinib—lung cancer	0.000217	0.00109	CcSEcCtD
Nadolol—Dry mouth—Paclitaxel—lung cancer	0.000217	0.00109	CcSEcCtD
Nadolol—Mood swings—Doxorubicin—lung cancer	0.000216	0.00109	CcSEcCtD
Nadolol—Diarrhoea—Vinorelbine—lung cancer	0.000216	0.00109	CcSEcCtD
Nadolol—Oedema—Paclitaxel—lung cancer	0.000212	0.00107	CcSEcCtD
Nadolol—Paraesthesia—Cisplatin—lung cancer	0.000212	0.00107	CcSEcCtD
Nadolol—Dyspnoea—Cisplatin—lung cancer	0.000211	0.00106	CcSEcCtD
Nadolol—Erectile dysfunction—Methotrexate—lung cancer	0.00021	0.00106	CcSEcCtD
Nadolol—Dry skin—Doxorubicin—lung cancer	0.000209	0.00105	CcSEcCtD
Nadolol—Hyperhidrosis—Etoposide—lung cancer	0.000209	0.00105	CcSEcCtD
Nadolol—Shock—Paclitaxel—lung cancer	0.000209	0.00105	CcSEcCtD
Nadolol—Dizziness—Vinorelbine—lung cancer	0.000209	0.00105	CcSEcCtD
Nadolol—Anorexia—Etoposide—lung cancer	0.000206	0.00104	CcSEcCtD
Nadolol—Body temperature increased—Irinotecan—lung cancer	0.000206	0.00104	CcSEcCtD
Nadolol—Decreased appetite—Cisplatin—lung cancer	0.000205	0.00103	CcSEcCtD
Nadolol—Hyperhidrosis—Paclitaxel—lung cancer	0.000205	0.00103	CcSEcCtD
Nadolol—Depression—Methotrexate—lung cancer	0.000203	0.00102	CcSEcCtD
Nadolol—Anorexia—Paclitaxel—lung cancer	0.000202	0.00102	CcSEcCtD
Nadolol—Hypotension—Etoposide—lung cancer	0.000202	0.00102	CcSEcCtD
Nadolol—Gastritis—Doxorubicin—lung cancer	0.000202	0.00102	CcSEcCtD
Nadolol—Pain—Cisplatin—lung cancer	0.000202	0.00102	CcSEcCtD
Nadolol—Vomiting—Vinorelbine—lung cancer	0.000201	0.00101	CcSEcCtD
Nadolol—Body temperature increased—Gemcitabine—lung cancer	0.0002	0.00101	CcSEcCtD
Nadolol—Rash—Vinorelbine—lung cancer	0.000199	0.001	CcSEcCtD
Nadolol—Dermatitis—Vinorelbine—lung cancer	0.000199	0.001	CcSEcCtD
Nadolol—Abdominal distension—Doxorubicin—lung cancer	0.000199	0.001	CcSEcCtD
Nadolol—Hypotension—Paclitaxel—lung cancer	0.000198	0.000999	CcSEcCtD
Nadolol—Syncope—Docetaxel—lung cancer	0.000198	0.000995	CcSEcCtD
Nadolol—Conjunctivitis—Methotrexate—lung cancer	0.000198	0.000995	CcSEcCtD
Nadolol—Sweating—Methotrexate—lung cancer	0.000195	0.000981	CcSEcCtD
Nadolol—Paraesthesia—Etoposide—lung cancer	0.000194	0.000979	CcSEcCtD
Nadolol—Loss of consciousness—Docetaxel—lung cancer	0.000194	0.000975	CcSEcCtD
Nadolol—Dyspnoea—Etoposide—lung cancer	0.000193	0.000972	CcSEcCtD
Nadolol—Cough—Docetaxel—lung cancer	0.000192	0.000968	CcSEcCtD
Nadolol—Insomnia—Paclitaxel—lung cancer	0.000192	0.000967	CcSEcCtD
Nadolol—Paraesthesia—Paclitaxel—lung cancer	0.000191	0.00096	CcSEcCtD
Nadolol—Hypertension—Docetaxel—lung cancer	0.00019	0.000958	CcSEcCtD
Nadolol—Agranulocytosis—Methotrexate—lung cancer	0.00019	0.000955	CcSEcCtD
Nadolol—Dyspnoea—Paclitaxel—lung cancer	0.000189	0.000953	CcSEcCtD
Nadolol—Decreased appetite—Etoposide—lung cancer	0.000188	0.000947	CcSEcCtD
Nadolol—Chest pain—Docetaxel—lung cancer	0.000188	0.000945	CcSEcCtD
Nadolol—Nausea—Vinorelbine—lung cancer	0.000187	0.000944	CcSEcCtD
Nadolol—Dyspepsia—Paclitaxel—lung cancer	0.000187	0.000941	CcSEcCtD
Nadolol—Body temperature increased—Cisplatin—lung cancer	0.000187	0.00094	CcSEcCtD
Nadolol—Asthenia—Irinotecan—lung cancer	0.000187	0.00094	CcSEcCtD
Nadolol—Fatigue—Etoposide—lung cancer	0.000187	0.00094	CcSEcCtD
Nadolol—Pain—Etoposide—lung cancer	0.000185	0.000932	CcSEcCtD
Nadolol—Constipation—Etoposide—lung cancer	0.000185	0.000932	CcSEcCtD
Nadolol—Decreased appetite—Paclitaxel—lung cancer	0.000185	0.000929	CcSEcCtD
Nadolol—Dry mouth—Docetaxel—lung cancer	0.000184	0.000924	CcSEcCtD
Nadolol—Fatigue—Paclitaxel—lung cancer	0.000183	0.000921	CcSEcCtD
Nadolol—Asthenia—Gemcitabine—lung cancer	0.000182	0.000916	CcSEcCtD
Nadolol—Pain—Paclitaxel—lung cancer	0.000182	0.000914	CcSEcCtD
Nadolol—Constipation—Paclitaxel—lung cancer	0.000182	0.000914	CcSEcCtD
Nadolol—Oedema—Docetaxel—lung cancer	0.00018	0.000906	CcSEcCtD
Nadolol—Weight increased—Doxorubicin—lung cancer	0.00018	0.000905	CcSEcCtD
Nadolol—Pruritus—Gemcitabine—lung cancer	0.000179	0.000903	CcSEcCtD
Nadolol—Diarrhoea—Irinotecan—lung cancer	0.000178	0.000896	CcSEcCtD
Nadolol—Shock—Docetaxel—lung cancer	0.000177	0.000891	CcSEcCtD
Nadolol—Visual impairment—Methotrexate—lung cancer	0.000176	0.000886	CcSEcCtD
Nadolol—Diarrhoea—Gemcitabine—lung cancer	0.000174	0.000873	CcSEcCtD
Nadolol—Dizziness—Irinotecan—lung cancer	0.000172	0.000866	CcSEcCtD
Nadolol—Anorexia—Docetaxel—lung cancer	0.000172	0.000863	CcSEcCtD
Nadolol—Body temperature increased—Etoposide—lung cancer	0.000171	0.000862	CcSEcCtD
Nadolol—Conjunctivitis—Doxorubicin—lung cancer	0.000171	0.000862	CcSEcCtD
Nadolol—Tinnitus—Methotrexate—lung cancer	0.00017	0.000857	CcSEcCtD
Nadolol—Asthenia—Cisplatin—lung cancer	0.00017	0.000854	CcSEcCtD
Nadolol—Sweating—Doxorubicin—lung cancer	0.000169	0.00085	CcSEcCtD
Nadolol—Hypotension—Docetaxel—lung cancer	0.000168	0.000846	CcSEcCtD
Nadolol—Body temperature increased—Paclitaxel—lung cancer	0.000168	0.000845	CcSEcCtD
Nadolol—Vomiting—Irinotecan—lung cancer	0.000166	0.000833	CcSEcCtD
Nadolol—Agranulocytosis—Doxorubicin—lung cancer	0.000164	0.000827	CcSEcCtD
Nadolol—Rash—Irinotecan—lung cancer	0.000164	0.000826	CcSEcCtD
Nadolol—Dermatitis—Irinotecan—lung cancer	0.000164	0.000825	CcSEcCtD
Nadolol—Insomnia—Docetaxel—lung cancer	0.000163	0.000819	CcSEcCtD
Nadolol—Diarrhoea—Cisplatin—lung cancer	0.000162	0.000814	CcSEcCtD
Nadolol—Paraesthesia—Docetaxel—lung cancer	0.000162	0.000813	CcSEcCtD
Nadolol—Alopecia—Methotrexate—lung cancer	0.000161	0.000812	CcSEcCtD
Nadolol—Vomiting—Gemcitabine—lung cancer	0.000161	0.000812	CcSEcCtD
Nadolol—Bradycardia—Doxorubicin—lung cancer	0.000161	0.00081	CcSEcCtD
Nadolol—Dyspnoea—Docetaxel—lung cancer	0.00016	0.000808	CcSEcCtD
Nadolol—Rash—Gemcitabine—lung cancer	0.00016	0.000805	CcSEcCtD
Nadolol—Dermatitis—Gemcitabine—lung cancer	0.00016	0.000804	CcSEcCtD
Nadolol—Dyspepsia—Docetaxel—lung cancer	0.000158	0.000797	CcSEcCtD
Nadolol—Decreased appetite—Docetaxel—lung cancer	0.000156	0.000787	CcSEcCtD
Nadolol—Asthenia—Etoposide—lung cancer	0.000155	0.000782	CcSEcCtD
Nadolol—Fatigue—Docetaxel—lung cancer	0.000155	0.000781	CcSEcCtD
Nadolol—Nausea—Irinotecan—lung cancer	0.000155	0.000778	CcSEcCtD
Nadolol—Pain—Docetaxel—lung cancer	0.000154	0.000775	CcSEcCtD
Nadolol—Constipation—Docetaxel—lung cancer	0.000154	0.000775	CcSEcCtD
Nadolol—Pruritus—Etoposide—lung cancer	0.000153	0.000771	CcSEcCtD
Nadolol—Visual impairment—Doxorubicin—lung cancer	0.000152	0.000767	CcSEcCtD
Nadolol—Asthenia—Paclitaxel—lung cancer	0.000152	0.000767	CcSEcCtD
Nadolol—Nausea—Gemcitabine—lung cancer	0.000151	0.000758	CcSEcCtD
Nadolol—Vomiting—Cisplatin—lung cancer	0.00015	0.000756	CcSEcCtD
Nadolol—Pruritus—Paclitaxel—lung cancer	0.00015	0.000756	CcSEcCtD
Nadolol—Vision blurred—Methotrexate—lung cancer	0.00015	0.000754	CcSEcCtD
Nadolol—Rash—Cisplatin—lung cancer	0.000149	0.00075	CcSEcCtD
Nadolol—Dermatitis—Cisplatin—lung cancer	0.000149	0.000749	CcSEcCtD
Nadolol—Diarrhoea—Etoposide—lung cancer	0.000148	0.000746	CcSEcCtD
Nadolol—Tinnitus—Doxorubicin—lung cancer	0.000147	0.000742	CcSEcCtD
Nadolol—Diarrhoea—Paclitaxel—lung cancer	0.000145	0.000731	CcSEcCtD
Nadolol—Dizziness—Etoposide—lung cancer	0.000143	0.000721	CcSEcCtD
Nadolol—Body temperature increased—Docetaxel—lung cancer	0.000142	0.000716	CcSEcCtD
Nadolol—Dizziness—Paclitaxel—lung cancer	0.00014	0.000707	CcSEcCtD
Nadolol—Nausea—Cisplatin—lung cancer	0.00014	0.000707	CcSEcCtD
Nadolol—Alopecia—Doxorubicin—lung cancer	0.00014	0.000703	CcSEcCtD
Nadolol—Cough—Methotrexate—lung cancer	0.000139	0.000698	CcSEcCtD
Nadolol—Vomiting—Etoposide—lung cancer	0.000138	0.000693	CcSEcCtD
Nadolol—Rash—Etoposide—lung cancer	0.000137	0.000687	CcSEcCtD
Nadolol—Dermatitis—Etoposide—lung cancer	0.000136	0.000687	CcSEcCtD
Nadolol—Flatulence—Doxorubicin—lung cancer	0.000136	0.000683	CcSEcCtD
Nadolol—Chest pain—Methotrexate—lung cancer	0.000135	0.000681	CcSEcCtD
Nadolol—Vomiting—Paclitaxel—lung cancer	0.000135	0.000679	CcSEcCtD
Nadolol—Rash—Paclitaxel—lung cancer	0.000134	0.000674	CcSEcCtD
Nadolol—Dermatitis—Paclitaxel—lung cancer	0.000134	0.000673	CcSEcCtD
Nadolol—Vision blurred—Doxorubicin—lung cancer	0.00013	0.000653	CcSEcCtD
Nadolol—Asthenia—Docetaxel—lung cancer	0.000129	0.00065	CcSEcCtD
Nadolol—Nausea—Etoposide—lung cancer	0.000129	0.000647	CcSEcCtD
Nadolol—Pruritus—Docetaxel—lung cancer	0.000127	0.000641	CcSEcCtD
Nadolol—Nausea—Paclitaxel—lung cancer	0.000126	0.000635	CcSEcCtD
Nadolol—Hyperhidrosis—Methotrexate—lung cancer	0.000125	0.000631	CcSEcCtD
Nadolol—Anorexia—Methotrexate—lung cancer	0.000124	0.000622	CcSEcCtD
Nadolol—Syncope—Doxorubicin—lung cancer	0.000123	0.000621	CcSEcCtD
Nadolol—Diarrhoea—Docetaxel—lung cancer	0.000123	0.00062	CcSEcCtD
Nadolol—Hypotension—Methotrexate—lung cancer	0.000121	0.00061	CcSEcCtD
Nadolol—Loss of consciousness—Doxorubicin—lung cancer	0.000121	0.000609	CcSEcCtD
Nadolol—Cough—Doxorubicin—lung cancer	0.00012	0.000604	CcSEcCtD
Nadolol—Dizziness—Docetaxel—lung cancer	0.000119	0.000599	CcSEcCtD
Nadolol—Hypertension—Doxorubicin—lung cancer	0.000119	0.000598	CcSEcCtD
Nadolol—Insomnia—Methotrexate—lung cancer	0.000117	0.00059	CcSEcCtD
Nadolol—Chest pain—Doxorubicin—lung cancer	0.000117	0.00059	CcSEcCtD
Nadolol—Paraesthesia—Methotrexate—lung cancer	0.000116	0.000586	CcSEcCtD
Nadolol—Dyspnoea—Methotrexate—lung cancer	0.000116	0.000582	CcSEcCtD
Nadolol—Dry mouth—Doxorubicin—lung cancer	0.000115	0.000577	CcSEcCtD
Nadolol—Vomiting—Docetaxel—lung cancer	0.000114	0.000576	CcSEcCtD
Nadolol—Dyspepsia—Methotrexate—lung cancer	0.000114	0.000575	CcSEcCtD
Nadolol—Rash—Docetaxel—lung cancer	0.000113	0.000571	CcSEcCtD
Nadolol—Dermatitis—Docetaxel—lung cancer	0.000113	0.000571	CcSEcCtD
Nadolol—Decreased appetite—Methotrexate—lung cancer	0.000113	0.000567	CcSEcCtD
Nadolol—Oedema—Doxorubicin—lung cancer	0.000112	0.000565	CcSEcCtD
Nadolol—Fatigue—Methotrexate—lung cancer	0.000112	0.000563	CcSEcCtD
Nadolol—Pain—Methotrexate—lung cancer	0.000111	0.000558	CcSEcCtD
Nadolol—Shock—Doxorubicin—lung cancer	0.00011	0.000556	CcSEcCtD
Nadolol—Hyperhidrosis—Doxorubicin—lung cancer	0.000109	0.000546	CcSEcCtD
Nadolol—Anorexia—Doxorubicin—lung cancer	0.000107	0.000539	CcSEcCtD
Nadolol—Nausea—Docetaxel—lung cancer	0.000107	0.000538	CcSEcCtD
Nadolol—Hypotension—Doxorubicin—lung cancer	0.000105	0.000528	CcSEcCtD
Nadolol—Body temperature increased—Methotrexate—lung cancer	0.000103	0.000516	CcSEcCtD
Nadolol—Insomnia—Doxorubicin—lung cancer	0.000102	0.000511	CcSEcCtD
Nadolol—Paraesthesia—Doxorubicin—lung cancer	0.000101	0.000508	CcSEcCtD
Nadolol—Dyspnoea—Doxorubicin—lung cancer	0.0001	0.000504	CcSEcCtD
Nadolol—Dyspepsia—Doxorubicin—lung cancer	9.89e-05	0.000498	CcSEcCtD
Nadolol—Decreased appetite—Doxorubicin—lung cancer	9.76e-05	0.000491	CcSEcCtD
Nadolol—Fatigue—Doxorubicin—lung cancer	9.68e-05	0.000487	CcSEcCtD
Nadolol—Pain—Doxorubicin—lung cancer	9.6e-05	0.000483	CcSEcCtD
Nadolol—Constipation—Doxorubicin—lung cancer	9.6e-05	0.000483	CcSEcCtD
Nadolol—Asthenia—Methotrexate—lung cancer	9.31e-05	0.000468	CcSEcCtD
Nadolol—Pruritus—Methotrexate—lung cancer	9.18e-05	0.000462	CcSEcCtD
Nadolol—Body temperature increased—Doxorubicin—lung cancer	8.88e-05	0.000447	CcSEcCtD
Nadolol—Diarrhoea—Methotrexate—lung cancer	8.87e-05	0.000447	CcSEcCtD
Nadolol—Dizziness—Methotrexate—lung cancer	8.58e-05	0.000432	CcSEcCtD
Nadolol—Vomiting—Methotrexate—lung cancer	8.25e-05	0.000415	CcSEcCtD
Nadolol—Rash—Methotrexate—lung cancer	8.18e-05	0.000412	CcSEcCtD
Nadolol—Dermatitis—Methotrexate—lung cancer	8.17e-05	0.000411	CcSEcCtD
Nadolol—Asthenia—Doxorubicin—lung cancer	8.06e-05	0.000406	CcSEcCtD
Nadolol—Pruritus—Doxorubicin—lung cancer	7.95e-05	0.0004	CcSEcCtD
Nadolol—Nausea—Methotrexate—lung cancer	7.7e-05	0.000388	CcSEcCtD
Nadolol—Diarrhoea—Doxorubicin—lung cancer	7.68e-05	0.000387	CcSEcCtD
Nadolol—Dizziness—Doxorubicin—lung cancer	7.43e-05	0.000374	CcSEcCtD
Nadolol—Vomiting—Doxorubicin—lung cancer	7.14e-05	0.000359	CcSEcCtD
Nadolol—Rash—Doxorubicin—lung cancer	7.08e-05	0.000356	CcSEcCtD
Nadolol—Dermatitis—Doxorubicin—lung cancer	7.07e-05	0.000356	CcSEcCtD
Nadolol—Nausea—Doxorubicin—lung cancer	6.67e-05	0.000336	CcSEcCtD
Nadolol—ADRB1—Signaling Pathways—NOTCH3—lung cancer	1.6e-05	0.000501	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FLT1—lung cancer	1.6e-05	0.000501	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—lung cancer	1.6e-05	0.0005	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KDR—lung cancer	1.59e-05	0.000498	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FGF9—lung cancer	1.59e-05	0.000497	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CG—lung cancer	1.59e-05	0.000496	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTA4—lung cancer	1.59e-05	0.000496	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APP—lung cancer	1.57e-05	0.00049	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOTCH3—lung cancer	1.57e-05	0.00049	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—lung cancer	1.57e-05	0.000489	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FGF9—lung cancer	1.55e-05	0.000486	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTA2—lung cancer	1.55e-05	0.000483	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—POMC—lung cancer	1.54e-05	0.000483	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—JUNB—lung cancer	1.52e-05	0.000474	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—POMC—lung cancer	1.51e-05	0.000472	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTA1—lung cancer	1.49e-05	0.000466	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—JUNB—lung cancer	1.48e-05	0.000464	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—lung cancer	1.48e-05	0.000462	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ABCC3—lung cancer	1.47e-05	0.000461	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CG—lung cancer	1.47e-05	0.000461	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CG—lung cancer	1.47e-05	0.000458	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—APC—lung cancer	1.47e-05	0.000458	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KIT—lung cancer	1.47e-05	0.000458	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—NRAS—lung cancer	1.47e-05	0.000458	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EGF—lung cancer	1.45e-05	0.000453	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CG—lung cancer	1.44e-05	0.00045	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AKR1C1—lung cancer	1.43e-05	0.000447	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CD—lung cancer	1.43e-05	0.000446	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—MAPK3—lung cancer	1.4e-05	0.000439	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—POMC—lung cancer	1.4e-05	0.000438	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—POMC—lung cancer	1.4e-05	0.000436	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CD—lung cancer	1.39e-05	0.000436	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—UGT1A1—lung cancer	1.39e-05	0.000434	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—STK11—lung cancer	1.38e-05	0.000431	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—BRAF—lung cancer	1.38e-05	0.000431	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—POMC—lung cancer	1.37e-05	0.000429	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6R—lung cancer	1.37e-05	0.000428	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6R—lung cancer	1.36e-05	0.000426	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CREBBP—lung cancer	1.36e-05	0.000425	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—lung cancer	1.36e-05	0.000425	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—STK11—lung cancer	1.35e-05	0.000421	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6R—lung cancer	1.34e-05	0.000418	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GNG11—lung cancer	1.34e-05	0.000418	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—EGFR—lung cancer	1.34e-05	0.000418	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FOXO3—lung cancer	1.33e-05	0.000416	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—lung cancer	1.31e-05	0.000411	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—MAP2K1—lung cancer	1.3e-05	0.000408	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FOXO3—lung cancer	1.3e-05	0.000407	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAP2K1—lung cancer	1.3e-05	0.000406	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CD—lung cancer	1.29e-05	0.000405	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CD—lung cancer	1.29e-05	0.000403	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PIK3CA—lung cancer	1.28e-05	0.000399	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—MAP2K1—lung cancer	1.27e-05	0.000399	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALDOA—lung cancer	1.27e-05	0.000398	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CD—lung cancer	1.27e-05	0.000396	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—APOA1—lung cancer	1.26e-05	0.000396	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—KRAS—lung cancer	1.26e-05	0.000394	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AVP—lung cancer	1.25e-05	0.00039	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CB—lung cancer	1.24e-05	0.000389	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NCOA3—lung cancer	1.24e-05	0.000386	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AVP—lung cancer	1.22e-05	0.000381	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CB—lung cancer	1.22e-05	0.00038	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ADCY1—lung cancer	1.2e-05	0.000376	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ABCG2—lung cancer	1.2e-05	0.000376	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IGF1R—lung cancer	1.2e-05	0.000375	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCL8—lung cancer	1.19e-05	0.000373	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HPGDS—lung cancer	1.18e-05	0.000369	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ENO2—lung cancer	1.18e-05	0.000369	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HES1—lung cancer	1.18e-05	0.000368	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IGF1R—lung cancer	1.17e-05	0.000367	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPP2R1B—lung cancer	1.17e-05	0.000366	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCL8—lung cancer	1.17e-05	0.000365	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PIK3CA—lung cancer	1.16e-05	0.000362	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—RAF1—lung cancer	1.16e-05	0.000361	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MDM2—lung cancer	1.15e-05	0.000361	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HES1—lung cancer	1.15e-05	0.00036	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—RAF1—lung cancer	1.15e-05	0.00036	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTT1—lung cancer	1.14e-05	0.000358	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—IL2—lung cancer	1.14e-05	0.000357	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ERBB2—lung cancer	1.14e-05	0.000356	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—RAF1—lung cancer	1.13e-05	0.000354	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GCLC—lung cancer	1.13e-05	0.000353	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP2A6—lung cancer	1.13e-05	0.000353	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CB—lung cancer	1.13e-05	0.000353	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MTOR—lung cancer	1.12e-05	0.000351	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CB—lung cancer	1.12e-05	0.000351	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—IL2—lung cancer	1.12e-05	0.000349	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	1.11e-05	0.000347	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CB—lung cancer	1.1e-05	0.000345	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCL8—lung cancer	1.08e-05	0.000339	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCL8—lung cancer	1.08e-05	0.000337	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ERBB3—lung cancer	1.08e-05	0.000337	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—HRAS—lung cancer	1.07e-05	0.000335	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ENO1—lung cancer	1.07e-05	0.000335	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—CREBBP—lung cancer	1.07e-05	0.000335	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCL8—lung cancer	1.06e-05	0.000332	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ERBB3—lung cancer	1.05e-05	0.00033	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—AKT1—lung cancer	1.04e-05	0.000326	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL2—lung cancer	1.04e-05	0.000324	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CASP3—lung cancer	1.03e-05	0.000323	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TERT—lung cancer	1.03e-05	0.000323	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL2—lung cancer	1.03e-05	0.000323	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6—lung cancer	1.03e-05	0.000321	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL2—lung cancer	1.01e-05	0.000317	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TERT—lung cancer	1.01e-05	0.000316	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCND1—lung cancer	1.01e-05	0.000314	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—JUN—lung cancer	1e-05	0.000314	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FGFR1—lung cancer	1e-05	0.000314	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ALB—lung cancer	1e-05	0.000313	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HIF1A—lung cancer	9.87e-06	0.000309	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FGFR1—lung cancer	9.81e-06	0.000307	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MMP9—lung cancer	9.76e-06	0.000305	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CDKN1A—lung cancer	9.73e-06	0.000304	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PTEN—lung cancer	9.7e-06	0.000303	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HIF1A—lung cancer	9.66e-06	0.000302	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP2E1—lung cancer	9.61e-06	0.000301	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APOA1—lung cancer	9.53e-06	0.000298	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NQO1—lung cancer	9.5e-06	0.000297	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—AKT1—lung cancer	9.47e-06	0.000296	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KDR—lung cancer	9.44e-06	0.000295	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APOA1—lung cancer	9.32e-06	0.000291	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EP300—lung cancer	9.26e-06	0.000289	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KDR—lung cancer	9.24e-06	0.000289	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	9.06e-06	0.000283	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SRC—lung cancer	9e-06	0.000281	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—VEGFA—lung cancer	8.77e-06	0.000274	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APC—lung cancer	8.7e-06	0.000272	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CG—lung cancer	8.7e-06	0.000272	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KIT—lung cancer	8.7e-06	0.000272	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—NRAS—lung cancer	8.7e-06	0.000272	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—STAT3—lung cancer	8.68e-06	0.000271	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NRAS—lung cancer	8.66e-06	0.000271	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EGF—lung cancer	8.6e-06	0.000269	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—STK11—lung cancer	8.57e-06	0.000268	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CG—lung cancer	8.51e-06	0.000266	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KIT—lung cancer	8.51e-06	0.000266	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APC—lung cancer	8.51e-06	0.000266	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—NRAS—lung cancer	8.51e-06	0.000266	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EGF—lung cancer	8.41e-06	0.000263	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—MAPK3—lung cancer	8.33e-06	0.000261	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAPK3—lung cancer	8.29e-06	0.000259	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—POMC—lung cancer	8.28e-06	0.000259	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—BRAF—lung cancer	8.18e-06	0.000256	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—MAPK3—lung cancer	8.15e-06	0.000255	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—POMC—lung cancer	8.1e-06	0.000253	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6R—lung cancer	8.08e-06	0.000253	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CREBBP—lung cancer	8.07e-06	0.000252	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MYC—lung cancer	8.07e-06	0.000252	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—BRAF—lung cancer	8e-06	0.00025	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTP1—lung cancer	7.93e-06	0.000248	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—EGFR—lung cancer	7.93e-06	0.000248	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6R—lung cancer	7.9e-06	0.000247	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CREBBP—lung cancer	7.89e-06	0.000247	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EGFR—lung cancer	7.89e-06	0.000247	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—EGFR—lung cancer	7.75e-06	0.000242	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CAT—lung cancer	7.71e-06	0.000241	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAP2K1—lung cancer	7.7e-06	0.000241	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CD—lung cancer	7.65e-06	0.000239	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CA—lung cancer	7.58e-06	0.000237	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAP2K1—lung cancer	7.53e-06	0.000235	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—KRAS—lung cancer	7.49e-06	0.000234	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CD—lung cancer	7.48e-06	0.000234	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KRAS—lung cancer	7.45e-06	0.000233	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CA—lung cancer	7.41e-06	0.000232	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—TYMS—lung cancer	7.37e-06	0.00023	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—KRAS—lung cancer	7.32e-06	0.000229	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTM1—lung cancer	7.28e-06	0.000228	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP1A1—lung cancer	6.91e-06	0.000216	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CA—lung cancer	6.88e-06	0.000215	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MDM2—lung cancer	6.85e-06	0.000214	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ERCC2—lung cancer	6.85e-06	0.000214	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CA—lung cancer	6.85e-06	0.000214	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RAF1—lung cancer	6.83e-06	0.000213	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ERBB2—lung cancer	6.75e-06	0.000211	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CA—lung cancer	6.73e-06	0.00021	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MDM2—lung cancer	6.7e-06	0.00021	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RAF1—lung cancer	6.68e-06	0.000209	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CB—lung cancer	6.67e-06	0.000208	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MTOR—lung cancer	6.67e-06	0.000208	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TP53—lung cancer	6.62e-06	0.000207	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ERBB2—lung cancer	6.61e-06	0.000207	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MTOR—lung cancer	6.52e-06	0.000204	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CB—lung cancer	6.52e-06	0.000204	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCL8—lung cancer	6.41e-06	0.0002	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—HRAS—lung cancer	6.36e-06	0.000199	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—HRAS—lung cancer	6.33e-06	0.000198	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCL8—lung cancer	6.27e-06	0.000196	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—HRAS—lung cancer	6.23e-06	0.000195	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AKT1—lung cancer	6.19e-06	0.000194	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CASP3—lung cancer	6.13e-06	0.000192	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL2—lung cancer	6.12e-06	0.000191	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6—lung cancer	6.09e-06	0.00019	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6—lung cancer	6.06e-06	0.00019	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AKT1—lung cancer	6.05e-06	0.000189	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CASP3—lung cancer	6e-06	0.000188	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL2—lung cancer	5.99e-06	0.000187	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCND1—lung cancer	5.97e-06	0.000187	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6—lung cancer	5.96e-06	0.000186	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—JUN—lung cancer	5.96e-06	0.000186	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOA1—lung cancer	5.92e-06	0.000185	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCND1—lung cancer	5.84e-06	0.000183	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—JUN—lung cancer	5.83e-06	0.000182	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MMP9—lung cancer	5.79e-06	0.000181	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CDKN1A—lung cancer	5.77e-06	0.000181	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTEN—lung cancer	5.76e-06	0.00018	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MMP9—lung cancer	5.67e-06	0.000177	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CDKN1A—lung cancer	5.65e-06	0.000177	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTEN—lung cancer	5.63e-06	0.000176	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AKT1—lung cancer	5.62e-06	0.000176	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AKT1—lung cancer	5.59e-06	0.000175	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AKT1—lung cancer	5.5e-06	0.000172	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EP300—lung cancer	5.49e-06	0.000172	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CG—lung cancer	5.41e-06	0.000169	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EP300—lung cancer	5.37e-06	0.000168	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SRC—lung cancer	5.34e-06	0.000167	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SRC—lung cancer	5.23e-06	0.000163	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—VEGFA—lung cancer	5.2e-06	0.000163	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—STAT3—lung cancer	5.15e-06	0.000161	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—POMC—lung cancer	5.15e-06	0.000161	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NRAS—lung cancer	5.14e-06	0.000161	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—VEGFA—lung cancer	5.09e-06	0.000159	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—STAT3—lung cancer	5.04e-06	0.000158	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NRAS—lung cancer	5.03e-06	0.000157	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CREBBP—lung cancer	5.01e-06	0.000157	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAPK3—lung cancer	4.92e-06	0.000154	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAPK3—lung cancer	4.81e-06	0.000151	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MYC—lung cancer	4.79e-06	0.00015	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CD—lung cancer	4.75e-06	0.000149	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALB—lung cancer	4.69e-06	0.000147	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MYC—lung cancer	4.68e-06	0.000146	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EGFR—lung cancer	4.68e-06	0.000146	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EGFR—lung cancer	4.58e-06	0.000143	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KRAS—lung cancer	4.42e-06	0.000138	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KRAS—lung cancer	4.33e-06	0.000135	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CB—lung cancer	4.14e-06	0.00013	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PTGS2—lung cancer	4.11e-06	0.000128	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CA—lung cancer	4.06e-06	0.000127	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CA—lung cancer	3.98e-06	0.000124	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TP53—lung cancer	3.93e-06	0.000123	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TP53—lung cancer	3.85e-06	0.00012	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HRAS—lung cancer	3.76e-06	0.000118	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HRAS—lung cancer	3.68e-06	0.000115	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6—lung cancer	3.6e-06	0.000113	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PTEN—lung cancer	3.58e-06	0.000112	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6—lung cancer	3.52e-06	0.00011	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—EP300—lung cancer	3.42e-06	0.000107	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKT1—lung cancer	3.32e-06	0.000104	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKT1—lung cancer	3.25e-06	0.000102	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CA—lung cancer	2.53e-06	7.9e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AKT1—lung cancer	2.06e-06	6.45e-05	CbGpPWpGaD
